Literature DB >> 15334054

Hepatitis C viral proteins interact with Smad3 and differentially regulate TGF-beta/Smad3-mediated transcriptional activation.

Pei-Lin Cheng1, Meng-Hsiung Chang, Chi-Hong Chao, Yan-Hwa Wu Lee.   

Abstract

Transforming growth factor-beta (TGF-beta) is a pleiotropic cytokine implicated as a pathogenic mediator in various liver diseases. Enhanced TGF-beta production and lack of TGF-beta responses are often observed during hepatitis C virus (HCV) infection. In this study, we demonstrate that TGF-beta-mediated transactivation is decreased in cells exogenously expressing the intact HCV polyprotein. Among 10 viral products of HCV, only core and nonstructural protein 3 (NS3) physically interact with the MH1 (Mad homology 1) region of the Smad3 and block TGF-beta/Smad3-mediated transcriptional activation through interference with the DNA-binding ability of Smad3, not the nuclear translocation. However, the interactive domain of NS3 extends to the MH2 (Mad homology 2) region of Smad3 and a distinction is found between effects mediated, respectively, by these two viral proteins. HCV core, in the presence or absence of TGF-beta, has a stronger suppressive effect on the DNA-binding and transactivation ability of Smad3 than NS3. Although HCV core, NS3, and the HCV subgenomic replicon all attenuate TGF-beta/Smad3-mediated apoptosis, only HCV core represses TGF-beta-induced G1 phase arrest through downregulation of the TGF-beta-induced p21 promoter activation. Along with this, HCV core, rather than NS3, exhibits a significant inhibitory effect on the binding of Smad3/Sp1 complex to the proximal p21 promoter in response to TGF-beta. In conclusion, HCV viral proteins interact with the TGF-beta signaling mediator Smad3 and differentially impair TGF-beta/Smad3-mediated transactivation and growth inhibition. This functional counteraction of TGF-beta responses provides insights into possible mechanisms, whereby the HCV oncogenic proteins antagonize the host defenses during hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334054     DOI: 10.1038/sj.onc.1208066

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  30 in total

1.  Kaposi's sarcoma-associated herpesvirus-encoded microRNA miR-K12-11 attenuates transforming growth factor beta signaling through suppression of SMAD5.

Authors:  Yunhua Liu; Rui Sun; Xianzhi Lin; Deguang Liang; Qiang Deng; Ke Lan
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

Review 2.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

3.  HTLV-1 bZIP factor enhances TGF-β signaling through p300 coactivator.

Authors:  Tiejun Zhao; Yorifumi Satou; Kenji Sugata; Paola Miyazato; Patrick L Green; Takeshi Imamura; Masao Matsuoka
Journal:  Blood       Date:  2011-06-24       Impact factor: 22.113

4.  Human papillomavirus type 5 E6 oncoprotein represses the transforming growth factor beta signaling pathway by binding to SMAD3.

Authors:  Jose-Andres Mendoza; Yves Jacob; Patricia Cassonnet; Michel Favre
Journal:  J Virol       Date:  2006-10-04       Impact factor: 5.103

Review 5.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

6.  Modulation of mitogen-activated protein kinase-activated protein kinase 3 by hepatitis C virus core protein.

Authors:  Huong T T Ngo; Long V Pham; Jong-Wook Kim; Yun-Sook Lim; Soon B Hwang
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

Review 7.  Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer.

Authors:  David R McGivern; Stanley M Lemon
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

8.  Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategies.

Authors:  Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader; Mohamed Hassan
Journal:  World J Hepatol       Date:  2012-12-27

9.  A Kaposi's sarcoma-associated herpesvirus microRNA and its variants target the transforming growth factor β pathway to promote cell survival.

Authors:  Xiufen Lei; Ying Zhu; Tiffany Jones; Zhiqiang Bai; Yufei Huang; Shou-Jiang Gao
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

10.  Liver cancer-derived hepatitis C virus core proteins shift TGF-beta responses from tumor suppression to epithelial-mesenchymal transition.

Authors:  Serena Battaglia; Nassima Benzoubir; Soizic Nobilet; Pierre Charneau; Didier Samuel; Anna Linda Zignego; Azeddine Atfi; Christian Bréchot; Marie-Françoise Bourgeade
Journal:  PLoS One       Date:  2009-02-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.